Basic Information
SALACLOVIR POWDER FOR SOLUTION FOR INFUSION 250MG/VIAL
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN14645P
October 7, 2014
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XJ05AB01
Company Information
Active Ingredients
Strength: 250 mg/ vial
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to valaciclovir – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** SALACLOVIR is indicated in non-immunocompromised patients for the treatment of - Severe initial genital herpes. - Varicella zoster virus infection. - Herpes simplex encephalitis. SALACLOVIR is indicated in immunocompromised patients for the treatment of - Herpes simplex infection. - Varicella zoster infection. - Prophylaxis of herpes simplex infection. - Herpes simplex encephalitis.